Püsem PATIR, Burçak Karaca, Alper Şener, Osman ZEKİOĞLU, Güray SAYDAM, Canfeza Sezgin

Enflamatuvar Meme Kanserinde Moleküler Alt Tip Dağılımı ve Siklooksijenaz-2 Ekspresyon Durumu

Anahtar Kelimeler:

Enflamatuvar meme kanseri, moleküler alt tip, siklooksijenaz-2

Molecular Subtype Distribution and Cyclooxygenase-2 Expression Situation in Inflammatory Breast Cancer

Objective: Inflammatory breast cancer (IBC) is a rare and aggressive form of locally advanced breast cancer. Currently, almost all women with IBC have lymph node involvement and approximately one-third have distant metastases. Therefore, there is still need for understanding of the molecular biology and new therapy alternatives in IBC. The purpose of this study was to determine the potential role of the cyclooxygenase-2 (COX-2) expression pattern in the aggressive and fatal course of IBC and to investigate the possibility of using COX-2 inhibitors as therapy options in the treatment of IBC. Materials and Methods: IBC samples obtained from breast cancer patients treated Between 2000-2009 in Ege University Faculty of Medicine Department of Medical Oncology were retrospectively evaluated. Immunohistochemical analysis was performed by a special breast cancer pathologist and manually assessed using an immunohistochemical scoring for both staining intensity and percentage. Results: In this study, the molecular subtypes identified in IBC patients were: basal (31%), luminal B/human epidermal growth factor receptor 2 (HER2)- (22%), luminal B/HER2+ (22%), HER2 (17%) and luminal A (8%). COX-2 expression was found to be positive in 92.6% of patients. Conclusion: In this context, it was concluded that the relatively high expression rate of COX-2 could be a reason for poor prognosis and also might lead to the use of COX-2 inhibitors not only as a single agent but also in combination with current chemotherapeutic agents in patients with IBC.

Keywords:

Inflammatory breast cancer, molecular subtype, cyclooxygenase-2,

PDF

___

1. Lee BJ, Tannenbaum EN. Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1924; 39: 580-95.
2. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97: 966-75.
3. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2006; 22: 9-23.
4. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010; 102: 627-37.
5. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95: 243-55.
6. Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akin S, et al. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON 2015; 20: 35-9.
7. Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 2003; 97: 2978-87.
8. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62: 1676-81.
9. Glover JA, Hughes CM, Cantwell MM, Murray LJ. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer 2011; 105: 13-7.
10. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65: 723-33.
11. Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 2011; 20: 66-70.
12. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000; 275: 14838-45.
13. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009; 20: 615- 20.
14. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004; 31(2 Suppl 7): 22- 9.

Meandros Medical And Dental Journal-Cover

ISSN: 2149-9063
Yayın Aralığı: 4
Başlangıç: 2000
Yayıncı: Aydın Adnan Menderes Üniversitesi

Arşiv

Sayıdaki Diğer Makaleler

Sunumu Ovarian Strumal Karsinoid: Olgu

Betül Bolat KÜÇÜKZEYBEK, Ayşe VATANSEVER, Aylin Orgen ÇALLI, Türkan REZANKO

Doksan Derece Konumlandırılmış Çift Plak ile Tespit ve Greftlemenin Humerus Cisim Kaynama Yokluğunun İyileşmesi Üzerine Etkinliği Nedir?

Mutlu ÇOBANOĞLU, Özgür ÖZBEY, Öner ŞAVK, Ferit ÖZGEZMEZ

Enflamatuvar Meme Kanserinde Moleküler Alt Tip Dağılımı ve Siklooksijenaz-2 Ekspresyon Durumu

Püsem PATIR, Burçak Karaca, Alper Şener, Osman ZEKİOĞLU, Güray SAYDAM, Canfeza Sezgin

İntravenöz Adenozin ve Oral Dipiridamol ile Miyokard Perfüzyon Sintigrafisi Uygulanan Hastalarda Hemodinamik Değişiklikler ile Yan Etkilerin Karşılaştırılması

Ahmet YANARATEŞ, Filiz HATİPOĞLU, Ayşegül AKGÜN, Kamil KUMANLIOĞLU